The number of claims lodged against physicians for allegedly causing iatrogenic ototoxic injury appears to be increas ing. Whi le Britis h and Canadian med ical organ izations had deve loped recomme ndations for limiting the use ofpotentially ototoxicototopical antibiotics, no systematic, evidence-based review of this issue had been performed in the United Stat es until our con sensus pane l was formed and was charged with this responsibility. Our findings were published in March 2004 (see "The panel 's recommendations") .' Our task was to answer two questions:
• Should potentially ototoxic antibiotics be used to treat ear disease in patients who have an open tympanic or mastoid cavi ty?
· lfpotentially ototoxic antibiotics are prescribed, shou ld limits or conditions be placed on their use?
Meth ods
The panel conducted separate reviews offour areas of research: animal studies,' ototoxicity in humans,' therapeutic efficacy,' and antibiotic resis tance.'
Animal studies. The data on an imal ototox icity are consistent. It is we ll established that aminoglycosides and some other agents are reliab ly and severe ly ototoxic in animals. But even though animal data are important, extrapolation to humans must be done with caut ion beca use of the differences in the round window membranes of animals and humans.
Ototox icity in humans. Some evi dence exists of both coc hlear and vestibular toxic ity in humans. The evidence for coch lear tox icity is sparse, but researchers at the University ofToronto have reported that aminoglycoside drops ca n cause significant vestib ular inj ury.
Therape utic efficacy. There is no evidence that aminoglycoside eardrops are more effective than f1uo roquino lone eardrops. Therefore, there is no j ustification for the use of a potentially ototoxic agent over a nontoxic agent in terms of efficacy.
A nti biotic resistance. We found no evidence that the use of ototopical agents induces or se lects for resis tant organ isms .
Conclusions
In addition to its four forma l recommendations, the pane l arrived at several other conclusions of note :
• For both clinical and medicolega l reasons, phys icians should not use an am inoglycoside-containing drop wit hout very good cause.These agents are associated with the onset of hearing loss and vest ibular injury.
• Neomyci n-containing drops can cause topical sensitization that can be difficu lt to distinguish from pers istent infection.
• The add ition of a steroid to an antibiotic drop can reduce the formation of granulation tiss ue, spee d the resolution of pain, and hasten the eradication of infection in some cases . 
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The panel's recommendations
Pursuant to its review of evidence-based research, the panel made four recommendations. ' Recommendation 1. When p ossible, top ical antibiotic preparations that are free ofpotential ototoxicity are preferable to those that do have the potential for otologic injury in patients with an open middle ear or mastoid.
Keep in mind , however, that this recommendation is not intended to unjustifi ably discourage the use of potenti ally ototoxic agents when clinic al circumstances warrant and when the judgment of the treating physician is that their use is appropriate in a particular case .
14· Volume 83 • Suppl 4
Such circumstances might include, but are certainly not limited to, previou s treatment failur e with quinolone drop s, culture results that sugg est that a qui no lone drop would not be appropriate, and the unavailability of potentially nontoxic preparations.
Recommendation 2. When a potentially ototoxi c antibiotic is chosen, it should be used only in infected ears and it should be discontinued shortly after the infection has resolved.
Recommendation 3. When a potentially ototoxi c antibiotic drop is prescribedfor a patient with an ope n middl e ear or masto id, the patient or parent should be warned ofthe risk ofototoxicity.
The patient orparent should be specifically instructed to call the physici an or return to the office ifthe patient develops (I ) dizziness or vertigo, (2) hearing loss or a worsening of hearing if such an impairment was already present, or (3) tinnitus. The treating physician should consider the poss ibility ofototoxic inj ury when evaluatin g these new or exacerbated symptoms.
Recommendation 4. If the tympanic membrane is known to be intact and the middle ear and mastoid are clos ed, the use of a potentially ototoxic preparation presents no risk ofototoxic injury.
